TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

You may be eligible if

• Patient is \> 18 years of age at the time the Informed Consent is signed
• Patient has agreed to abide by all protocol-required procedures, including study-related assessments, and management by the treating institution for the duration of the study and LTFU
• Histologically confirmed NHL or ALL
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Patient must have adequate organ function as indicated by the laboratory values in the clinical protocol
• Patient must be fit for leukapheresis and have adequate venous access for cell collection
• Patient must have evidence of CD19 expression
• Prior CD19-directed CAR T therapy is allowed